EGFR and colorectal carcinoma: Other agents that operate by blocking the tyrosine kinase domain of epidermal growth factor receptor (EGFR) utilizing monoclonal antibodies, such as cetuximab or panitumumab, are also available for the treatment of CRC [10,11].